WTO's vaccine patent waiver may have little impact on ground now: Industry

Serum Institute says while patent waivers for Covid-19 vaccines are 'encouraging', demand for vaccines today is declining

vaccine
Premium

Legal experts point out that it needs to be seen what exactly a ‘partial’ waiver is.

Sohini Das Mumbai
The World Trade Organization’s (WTO’s) green light for a politically-significant deal of a patent waiver for manufacturing Covid vaccines may have little impact in boosting vaccine production immediately or getting new technologies for manufacture, according to experts.

Commerce and Industries Minister Piyush Goyal said the Trade-Related Aspects of Intellectual Property Rights (Trips) decision will boost vaccine equity, accessibility and affordability. “It will enable ease of authorisation for production of patented vaccines and India can produce for domestic requirements and exports,” he said.

The minister said a country can authorise production of vaccines patented elsewhere and no consent is required. Also,

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jun 17 2022 | 4:54 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com